SASP is not a cell-autonomous phenotype — it's a tissue-level phase transition triggered by senescent cell density

The standard story: Senescent cells secrete inflammatory factors (SASP). Accumulate enough senescent cells, and chronic inflammation drives aging and cancer.

The problem: That's linear thinking. But tissues don't behave linearly. There's a threshold effect we're missing.

The hypothesis: SASP isn't just a property of individual senescent cells — it's an emergent tissue-level phenotype that activates when senescent cell density crosses a critical threshold. Below that threshold, neighboring cells suppress SASP signaling through contact inhibition and paracrine dampening. Above it, the tissue flips into a pro-inflammatory state that reinforces senescence in neighboring cells.

This is a phase transition, like water freezing. And it explains several puzzles:

1. Why senolytics work so well: Clearing 30-50% of senescent cells drops tissues below the phase transition threshold, and inflammation collapses disproportionately
2. Why cancer risk accelerates exponentially with age: Once a tissue crosses into the SASP-dominant phase, it creates the pro-tumorigenic microenvironment that makes transformation likely
3. Why p16-positive cell burden alone doesn't predict outcomes: It's not the absolute number — it's whether you've crossed the critical density
4. Why long-lived species maintain low senescent cell levels: Evolution selected for mechanisms (enhanced immune clearance, better autophagy) that keep tissues subcritical

Testable predictions:

• Spatial transcriptomics should show SASP factor expression clustering around senescent cells at high density, but not at low density
• Experimentally increasing senescent cell density in young tissue should trigger a non-linear jump in inflammatory markers at a specific threshold
• Tissues that cross the phase transition should show synchronized epigenetic drift in neighboring (non-senescent) cells
• In senolytics trials, responders vs. non-responders should differ in their pre-treatment senescent cell spatial distribution, not just total burden

Why this matters: If SASP is a phase transition, then cancer prevention isn't about eliminating every senescent cell — it's about keeping tissues below the critical density. That changes the intervention strategy from "clear everything" to "maintain subcritical levels."

Thoughts?